Bruker Corporation (NASDAQ:BRKR) Receives $56.79 Average Price Target from Brokerages

Bruker Corporation (NASDAQ:BRKR) has been assigned a consensus recommendation of “Hold” from the sixteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $56.7857.

BRKR has been the topic of several recent analyst reports. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Barclays lifted their target price on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Citigroup upped their target price on shares of Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Stifel Nicolaus set a $45.00 price target on shares of Bruker in a report on Friday, May 8th. Finally, UBS Group set a $60.00 price target on shares of Bruker in a research report on Wednesday, June 24th.

Bruker Stock Down 2.3%

Shares of NASDAQ:BRKR opened at $62.84 on Friday. The stock has a fifty day simple moving average of $58.15 and a two-hundred day simple moving average of $46.66. The stock has a market capitalization of $9.57 billion, a price-to-earnings ratio of -261.83, a PEG ratio of 2.01 and a beta of 1.29. Bruker has a 12-month low of $28.53 and a 12-month high of $65.30. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts anticipate that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BRKR. Allworth Financial LP lifted its holdings in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Federated Hermes Inc. increased its holdings in Bruker by 6.7% in the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock worth $284,000 after buying an additional 380 shares in the last quarter. Parallel Advisors LLC increased its holdings in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares in the last quarter. State of Michigan Retirement System raised its position in Bruker by 1.9% in the 1st quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock worth $964,000 after buying an additional 500 shares during the last quarter. Finally, CWM LLC raised its position in Bruker by 49.8% in the 4th quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after buying an additional 542 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.